United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's earnings and revenue fell short of Wall Street expectations, disappointing investors and triggering a sell-off.
The company reported earnings per share (EPS) of $6.41, missing the FactSet consensus estimate of $6.94. While this represents an increase from $5.85 in the same quarter last year, it failed to meet market expectations. Revenue for the quarter came in at $798.6 million, up 11.7% year-over-year but falling short of the analyst consensus of $804.3 million.
Despite reporting record total revenue and highlighting strong performance in key products like Tyvaso DPI, which saw 22% growth over Q2 2024, investors seemed to focus on the earnings miss. The company's announcement of a new $1 billion share repurchase program, expiring in March 2026, did little to offset the negative sentiment. As United Therapeutics continues to invest in its pipeline, including ongoing Phase 3 studies for Nebulized Tyvaso and ralinepag, investors will be closely watching for updates on these potential growth drivers in the coming quarters.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.